346 related articles for article (PubMed ID: 30889383)
1. DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors.
Pillay N; Tighe A; Nelson L; Littler S; Coulson-Gilmer C; Bah N; Golder A; Bakker B; Spierings DCJ; James DI; Smith KM; Jordan AM; Morgan RD; Ogilvie DJ; Foijer F; Jackson DA; Taylor SS
Cancer Cell; 2019 Mar; 35(3):519-533.e8. PubMed ID: 30889383
[TBL] [Abstract][Full Text] [Related]
2. Specific killing of DNA damage-response deficient cells with inhibitors of poly(ADP-ribose) glycohydrolase.
Gravells P; Grant E; Smith KM; James DI; Bryant HE
DNA Repair (Amst); 2017 Apr; 52():81-91. PubMed ID: 28254358
[TBL] [Abstract][Full Text] [Related]
3. PARP and PARG inhibitors in cancer treatment.
Slade D
Genes Dev; 2020 Mar; 34(5-6):360-394. PubMed ID: 32029455
[TBL] [Abstract][Full Text] [Related]
4. Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models.
Coulson-Gilmer C; Morgan RD; Nelson L; Barnes BM; Tighe A; Wardenaar R; Spierings DCJ; Schlecht H; Burghel GJ; Foijer F; Desai S; McGrail JC; Taylor SS
J Exp Clin Cancer Res; 2021 Oct; 40(1):323. PubMed ID: 34656146
[TBL] [Abstract][Full Text] [Related]
5. Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.
Gogola E; Duarte AA; de Ruiter JR; Wiegant WW; Schmid JA; de Bruijn R; James DI; Guerrero Llobet S; Vis DJ; Annunziato S; van den Broek B; Barazas M; Kersbergen A; van de Ven M; Tarsounas M; Ogilvie DJ; van Vugt M; Wessels LFA; Bartkova J; Gromova I; Andújar-Sánchez M; Bartek J; Lopes M; van Attikum H; Borst P; Jonkers J; Rottenberg S
Cancer Cell; 2018 Jun; 33(6):1078-1093.e12. PubMed ID: 29894693
[TBL] [Abstract][Full Text] [Related]
6. The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.
Parmar K; Kochupurakkal BS; Lazaro JB; Wang ZC; Palakurthi S; Kirschmeier PT; Yang C; Sambel LA; Färkkilä A; Reznichenko E; Reavis HD; Dunn CE; Zou L; Do KT; Konstantinopoulos PA; Matulonis UA; Liu JF; D'Andrea AD; Shapiro GI
Clin Cancer Res; 2019 Oct; 25(20):6127-6140. PubMed ID: 31409614
[TBL] [Abstract][Full Text] [Related]
7. Selective small molecule PARG inhibitor causes replication fork stalling and cancer cell death.
Houl JH; Ye Z; Brosey CA; Balapiti-Modarage LPF; Namjoshi S; Bacolla A; Laverty D; Walker BL; Pourfarjam Y; Warden LS; Babu Chinnam N; Moiani D; Stegeman RA; Chen MK; Hung MC; Nagel ZD; Ellenberger T; Kim IK; Jones DE; Ahmed Z; Tainer JA
Nat Commun; 2019 Dec; 10(1):5654. PubMed ID: 31827085
[TBL] [Abstract][Full Text] [Related]
8. DNA replication stress and emerging prospects for PARG inhibitors in ovarian cancer therapy.
Pillay N; Brady RM; Dey M; Morgan RD; Taylor SS
Prog Biophys Mol Biol; 2021 Aug; 163():160-170. PubMed ID: 33524442
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of poly(ADP-ribose) polymerase-1 or poly(ADP‑ribose) glycohydrolase individually, but not in combination, leads to improved chemotherapeutic efficacy in HeLa cells.
Feng X; Koh DW
Int J Oncol; 2013 Feb; 42(2):749-56. PubMed ID: 23254695
[TBL] [Abstract][Full Text] [Related]
10. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
Haynes B; Murai J; Lee JM
Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007
[TBL] [Abstract][Full Text] [Related]
11. Discovery and structure-activity relationships of modified salicylanilides as cell permeable inhibitors of poly(ADP-ribose) glycohydrolase (PARG).
Steffen JD; Coyle DL; Damodaran K; Beroza P; Jacobson MK
J Med Chem; 2011 Aug; 54(15):5403-13. PubMed ID: 21692479
[TBL] [Abstract][Full Text] [Related]
12. PARG Inhibitors and Functional PARG Inhibition Models.
Sasaki Y; Hozumi M; Fujimori H; Murakami Y; Koizumi F; Inoue K; Masutani M
Curr Protein Pept Sci; 2016; 17(7):641-653. PubMed ID: 27817742
[TBL] [Abstract][Full Text] [Related]
13. Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer.
Martincuks A; Zhang C; Austria T; Li YJ; Huang R; Lugo Santiago N; Kohut A; Zhao Q; Borrero RM; Shen B; Cristea M; Wang EW; Song M; Rodriguez-Rodriguez L; Yu H
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580335
[TBL] [Abstract][Full Text] [Related]
14. A high-throughput screening-compatible homogeneous time-resolved fluorescence assay measuring the glycohydrolase activity of human poly(ADP-ribose) glycohydrolase.
Stowell AI; James DI; Waddell ID; Bennett N; Truman C; Hardern IM; Ogilvie DJ
Anal Biochem; 2016 Jun; 503():58-64. PubMed ID: 27036617
[TBL] [Abstract][Full Text] [Related]
15. Targeting poly(ADP-ribose) glycohydrolase to draw apoptosis codes in cancer.
Tanuma SI; Shibui Y; Oyama T; Uchiumi F; Abe H
Biochem Pharmacol; 2019 Sep; 167():163-172. PubMed ID: 31176615
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel poly(ADP-ribose) glycohydrolase inhibitors by a quantitative assay system using dot-blot with anti-poly(ADP-ribose).
Okita N; Ashizawa D; Ohta R; Abe H; Tanuma S
Biochem Biophys Res Commun; 2010 Feb; 392(4):485-9. PubMed ID: 20079708
[TBL] [Abstract][Full Text] [Related]
17. Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) - Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy.
Harrision D; Gravells P; Thompson R; Bryant HE
Front Mol Biosci; 2020; 7():191. PubMed ID: 33005627
[TBL] [Abstract][Full Text] [Related]
18. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
Papa A; Caruso D; Strudel M; Tomao S; Tomao F
J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
[TBL] [Abstract][Full Text] [Related]
19. Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib via Regulation of Rad51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells.
Cho HY; Kim YB; Park WH; No JH
Cancer Res Treat; 2021 Jul; 53(3):819-828. PubMed ID: 33332934
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of poly(ADP-ribose) glycohydrolase (PARG) specifically kills BRCA2-deficient tumor cells.
Fathers C; Drayton RM; Solovieva S; Bryant HE
Cell Cycle; 2012 Mar; 11(5):990-7. PubMed ID: 22333589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
